It is now widely known that metabolic surgery provides a profound reduction in type 2 diabetes metrics among obese individuals, with durable published remissions in a high percentage of patients beyond 10 years. Metabolic surgery reverses the type 2 diabetes completely in the first year in most obese individuals, and surgery induces a profound survival advantage, as well as dramatic reductions in blindness, kidney failure and amputations compared to medically managed diabetics. Low BMI individuals with type 2 diabetes have also enjoyed a significant improved clinical outcome with metabolic surgery compared to medical management, and a recent 2019 meta-analysis describes the published results in Asian patient with type 2 diabetes and a BMI under 30.
Metabolic surgery induces a significant reduction in all metrics of type 2 diabetes among Asians with an average BMI of 26. The published results are sustained at 2 years, in studies reported in this paper thus far. BMI, Glucose, and Hemoglobin A1c al drop considerably and remain lowered two years later.